Although CXCL1 has been reported, our research has important therapeutic implications: by pinpointing senescence drivers of colitis-associated carcinogenesis, and our study opens up new avenues for intervention (for example, targeting senescent cells or their secretory factors) to potentially prevent or delay UC progression to CRC, a clear advantage over previous gene sets that mostly served as diagnostic markers and revealing actionable pathogenic processes. This evidence concerns the gene CXCL1 and colitis.